SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study

Dib, M.; Corre, Nicole Le; Ortiz, Catalina; García, Daniel; Ferrés, Marcela; Martínez-Valdebenito, Constanza; Ruiz-Tagle, Cinthya; Ojeda, María José; Espinoza, Manuel; Jara, Aquiles; Arab, Juan Pablo; Rabagliati, Ricardo; Vizcaya, Cecilia; Ceballos, María Elena; Sarmiento, Mauricio; Mondaca, Sebastián; Viñuela, Macarena; Pastore, Antonia; Szwarcfiter, Vania; Galdames, Elizabeth; Barrera, Aldo; Castro, Pablo; Gálvez, Nicolás M. S.; Soto, Jorge A.; Bueno, Susan M.; Kalergis, Alexis M.; Nervi, Bruno; Balcells, María Elvira

doi:10.1016/j.lana.2022.100371

Cited by 15 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Impaired cellular and humoral immune responses after two-dose vaccination schemes are extensively reported in CKD patients, showing a stronger immune response in HD patients [ 9 , 17 , 18 , 21 ]. Most studies included mRNA vaccinated patients, and only a few studies evaluated the immune responses of CoronaVac schemes in a cohort that included KT patients [ 16 , 36 , 37 , 38 , 39 , 40 ] and/or HD patients [ 14 , 41 , 42 , 43 , 44 ]. Here we show that HD and KT patients have a reduced humoral and cellular immune response after a primary scheme with either CoronaVac or BNT162b2 that increases after a BNT162b2 booster.…”

Section: Discussionmentioning

confidence: 99%

“…Another study showed that KT patients had significantly decreased frequencies of spike-specific IFN-γ + TNF-α + IL-2 + polyfunctional T cells compared to HD and healthy controls, and all of them had received two doses of BNT162b2 [ 17 ]. Comparison between vaccination schedules in a Chilean cohort of solid-organ transplant recipients, including KT patients, showed that homologous BNT162b2 scheme induced higher humoral responses but similar specific IFN-γ or IL-2 T cell responses compared to heterologous scheme [ 37 ]. Comparison of polyfunctional T cells between these two schemes has not been performed; therefore, our study is the first to show differences in a CKD cohort.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients

et al. 2023

View full text Add to dashboard Cite

Chronic kidney disease (CKD) patients have an increased risk of morbidity and mortality following SARS-CoV-2 infection. Vaccination in these patients is prioritized, and monitoring of the immune response is paramount to define further vaccination strategies. This prospective study included a cohort of 100 adult CKD patients: 48 with kidney transplant (KT) and 52 on hemodialysis without prior COVID-19. The patients were assessed for humoral and cellular immune responses after four months of an anti-SARS-CoV-2 primary two-dose vaccination scheme (CoronaVac or BNT162b2) and one month after a booster third dose of BNT162b2 vaccine. We identified poor cellular and humoral immune responses in the CKD patients after a primary vaccination scheme, and these responses were improved by a booster. Robust polyfunctional CD4+ T cell responses were observed in the KT patients after a booster, and this could be attributed to a higher proportion of the patients having been vaccinated with homologous BNT162b2 schemes. However, even after the booster, the KT patients exhibited lower neutralizing antibodies, attributable to specific immunosuppressive treatments. Four patients suffered severe COVID-19 despite three-dose vaccination, and all had low polyfunctional T-cell responses, underscoring the importance of this functional subset in viral protection. In conclusion, a booster dose of SARS-CoV-2 mRNA vaccine in CKD patients improves the impaired humoral and cellular immune responses observed after a primary vaccination scheme.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…By 9 October 2021, the world data reported that SARS-CoV-2S-based mRNA vaccine types were administered to 233.39 million people for the Pfizer-BioNTech and 152.84 million for the Moderna vaccine. This type of vaccine is indicated for frail patients, such as those with autoimmune diseases, transplant recipients, and patients living with HIV since they showed higher efficacy and higher estimated effectiveness ( 13 – 15 ). Thus, knowing predisposition factors that could determine the development of severe cardiac adverse events upon mRNA vaccination is of great relevance for vaccination programs.…”

Section: Discussionmentioning

confidence: 99%

Myocardial infarction or myocarditis? A case report and review of a myocardial adverse event associated with mRNA vaccine

Badaró

Novaes

Andrade³

et al. 2023

Front. Med.

View full text Add to dashboard Cite

A 23-year-old man started with chest pain 8 h after his first Pfizer-BioNTech COVID-19 vaccination. ECG evaluation showed sinus tachycardia with ST-segment elevation in D1, AVL, V5, and V6, the findings compatible with acute subepicardial myocardial damage. However, cardiac MRI documented myocardial fibrosis, with cardiac late enhancement non-ischemic pattern with diffuse edema. He had no other symptoms to suggest another etiology than the vaccination. The patient was hospitalized and received corticosteroid (prednisolone) daily. Then, 2 weeks after hospitalization, all laboratory parameters and ECG were normal and the patient was discharged from the hospital. The patient had a history of Wolf-Parkinson White that was corrected with ablation when he was 11 years old. This report calls attention to myocardial adverse reaction risk for mRNA COVID-19 vaccines for people with a previous cardiac disease history.

show abstract

“…Our study was different in that the testing for neutralizing antibodies was against the current variant omicron. Dib et al reported a better humoral response after three doses of mRNA vaccines than after heterologous regimens in SOT recipients 19 . However, in countries in which only inactivated vaccines were available at the beginning of the pandemic, patients had access to the mRNA vaccine only as the third dose, and studies indicated better immunogenicity after mRNA boosters.…”

Section: Discussionmentioning

confidence: 99%

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses Among Transplant Recipients Who Had Received Two Doses of CoronaVac

Erol

Kuloğlu

Kayaaslan

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: We evaluated neutralizing antibody and anti-spike antibody (anti-S) response against omicron variant in solid organ (SOT) or hematopoietic stem cell (HSTC) receivers after third dose of BNT162b2 (BNT) or CoronaVac (CV) following two doses of CV. Methods: In total, 95 participants who underwent SOT (n=62; 44 liver, 18 kidney) or HSCT (n=27; 5 allogeneic, 22 autologous) were included from five centers in Turkey. The median time between third doses and serum sampling was 154 days. The vaccine-induced antibody responses of both neutralizing antibodies and Anti-Spike antibodies were assessed by plaque neutralizing assay and immunoassay. Results: Neutralizing antibody and anti-spike IgG levels were significantly higher in transplant patients receiving BNT compared to those receiving CV (GMT:26.76 vs 10.89; p=0.03 and 2116 Au/ml vs 172.1 Au/ml; p<0.001). Solid organ transplantation recipients, particularly liver transplant recipients, showed lower antibody levels than HSCT recipients. Thus, among HSCT recipients, the GMT after BNT was 91.29 and it was 15.81 in the SOT group (p<0.001). In SOT, antibody levels after BNT in kidney transplantation recipients was significantly higher than that in liver transplantation recipients (GMT:48.32 vs 11.72) (p<0.001). Besides, the neutralizing antibody levels after CV were very low (GMT: 10.81) in kidney transplantation recipients and below the detection limit (<10) in liver transplant recipients. There was a weak correlation between the neutralizing and anti-Spike antibody responses (r=0.36). Conclusion: This study highlights the superiority of BNT responses against omicron as a third dose among transplant recipients after two doses of CV. Lack of neutralizing antibody against omicron after CV in liver transplant recipients should be taken into consideration particularly in countries where inactivated vaccines are available in addition to mRNA vaccines.

show abstract

SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study

Cited by 15 publications

References 26 publications

A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients

A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients

Myocardial infarction or myocarditis? A case report and review of a myocardial adverse event associated with mRNA vaccine

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses Among Transplant Recipients Who Had Received Two Doses of CoronaVac

Contact Info

Product

Resources

About